All News
New Advances in Ultrasound Diagnostics for Psoriatic Arthritis
d
ACR Press Release
Two pivotal studies led by an international team of rheumatology experts will be presented at ACR Convergence 2025, showcasing major strides in the ultrasound-based diagnosis of enthesitis in psoriatic arthritis (PsA).
Read Article
#0850 Single-cell RNA-seq of RA synovium uncovers a new biomarker & therapeutic target: PHIF
Made by Tph cells, drives macrophage activation and mirrors disease severity.
Big step forward in understanding RA immunopathogenesis. @RheumNow #ACR25 https://t.co/KtyxU0Lqly
Mrinalini Dey DrMiniDey ( View Tweet)
This retrospective study evaluated incidence of MACE & mortality among PsA pts on GLP-1RAs vs non-GLP-1RAs
After propensity score matching, pts on GLP-1RAs = ⬇️ risk of developing MACE & ⬇️ mortality vs. non GLP-1RAs
Interesting data, More research reqd
#ACR25 @RheumNow Abs0849 https://t.co/hiPpQH0K3O
Links:
sheila RHEUMarampa ( View Tweet)
TriNetX database 4000+ pts PsA + GLP-1 RA & 86000+ PsA non GLP-1 ctrls
Without much surprise GLP-1 treated pts had lower risk of MACE and death
Observational, retrospective study.
Now awaiting the prospective evidence.
RCT on the way but capturing MACE and death are always https://t.co/GWbAMC1mJK
Aurelie Najm AurelieRheumo ( View Tweet)
Next Generation T-Cell Engager: The Future https://t.co/gcrfzV6MSJ via @YouTube
@alhkim great to see you and hearing all about new T cell Engager , feasibility and less toxicity.
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#0851
Urinary Tenascin C predicts kidney function loss in lupus nephritis
170 AMP-LN patients: Tenascin C (from renal myofibroblasts) was the top predictor of eGFR decline (HR 4.6)
Proteomic 11-marker risk score (AUC 0.91) outperformed proteinuria for prognosis #ACR25 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
In the #ACR25 Great AI debate, @RADoctor shows automated ultrasound scanning - one legitimately promising application ready very soon.
I’ve written about this work (ARTHUR/DIANA) for @RheumNow last year - check it out:
https://t.co/Zq4ywEjspi https://t.co/3RYCVunE3a
Links:
David Liew drdavidliew ( View Tweet)
#0852 LEVI-04, a novel p75NTR-Fc fusion protein, significantly reduces MRI bone marrow lesions in knee #OA 🦵📉
Phase II RCT (n=518): dose-dependent BML reduction (p<0.001) + correlated improvement in pain & function. Promising structure-modifying OA therapy
@RheumNow #ACR25 https://t.co/huA8OaFGSd
Mrinalini Dey DrMiniDey ( View Tweet)
@JYazdanyMD in the #ACR25 Great AI Debate details out three key risks of AI in rheumatology:
- bias at scale
- erosion of skills
- data regulatory issues
(for what it’s worth, amongst all the potential upside, I think it’s very real. It’s up to us to make it better)
@RheumNow https://t.co/FyNes40Z7q
David Liew drdavidliew ( View Tweet)
In this ph2 trial of LEVI-04 for knee #osteoarthritis,
At wk 20, LEVI-04 ⬇️ bone marrow lesions (BML), greater ⬇️ in BML area even w/ higher KL grades
Promising treatment.
#ACR25 @RheumNow Abs0852 #ACRBest https://t.co/MrmLPlFiDs
Links:
sheila RHEUMarampa ( View Tweet)
Summary take home points by Dr Highland
1. PAH and PH-ILD are associated with high mortality in patients with SARDs
2. Multimodal and early screening is recommended
3. “It takes a village” work with Pulm and Cardiology colleagues
@RheumNow #ACR2025 https://t.co/Xa7TecMOIe
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
In the #ACR25 Great AI Debate, @RADoctor and @JYazdanyMD prepared independently, but in consecutive moments agree (in a very illustrative way):
guardrails - they need to happen
@RheumNow https://t.co/ccLLC3adxG
Links:
David Liew drdavidliew ( View Tweet)
The CLASSIC study (n=1015, 27 countries) validated revised ASAS-SPARTAN axSpA criteria. Final model achieved 79.5% sensitivity & 90.4% specificity vs global diagnosis. MRI SIJ (active + structural) was strongest predictor. HLA-B27, CRP, IBD, uveitis also included. Abstract#0854 https://t.co/GjSHE2ihVI
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#0853 Olink proteomics in anti-Ro+ pregnancies identifies macrophage-derived IL-6 & CCL3 as serum predictors of foetal AV block
These pro-inflammatory proteins predicted fAVB independent of maternal diagnosis or Ab titres, pointing to new pathogenic pathways. @RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
#1627 SLR informing the 2025 @eular_org recommendations for PMR & LVV 🔍
141 studies (30 RCTs) reviewed: new & further evidence for IL-6, JAK & B-cell-targeted therapies. Data will underpin updated management guidance. @RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
#0854 @Official_ASAS & @SPARTAN_Updates revised #axSpA criteria meet targets: Sn 79.5% / Sp 90.4%.
Imaging is central (SIJ MRI + structural lesions) with focused clinical items: HLA-B27, IBP, uveitis, IBD, heel enthesitis, psoriasis, ↑CRP
@RheumNow #ACR25 https://t.co/i2d12y9HcD
Mrinalini Dey DrMiniDey ( View Tweet)
Summary of (some) drugs in the pipeline for management of PAH. Slide credits: Dr Benjamin Freed @RheumNow #ACR2025 https://t.co/qazQNk4ovR
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
#1614 Another SLR informing the 2025 EULAR recommendations for PMR & LVV 🧭
Fast-track clinics cut blindness & diagnostic delays; multimodal imaging pathways outperform biopsy alone. Key data shaping future referral & diagnosis guidance. @RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
What is better in #PsA post #TNFi?
#RCT of #secukinumab v #ustekinumab
The big 🤔? #IL17Ai vs IL12/23i
🏆 #Cosentyx
✈️✅PASI
⚜️✅ACR50
Will H2H studies change our #prescribing?🤷♀️
#rheums Rx #IL17i>#IL12i/23i vs #derms
#ACRBest #ACR25 @RheumNow @ACRheum abst#LB06 https://t.co/RpC8ymDc7H
Janet Pope Janetbirdope ( View Tweet)
#ACR25 Abstr#1525 Find me at poster hall. Super-responders exist with rituximab, not just confined to CAR-T! Our cohort study = 23/114 (20%) had resp duration >3-yrs; 15/23 were IS-Free. Poor prognostics (Non-White, APS) & shorter #SLE duration predicted super-tesponse @RheumNow https://t.co/nJQFmiIj2n
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
